High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease

94Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Two patients with severe Crohn disease, defined by a Crohn Disease Activity Index (CDAI) higher than 250 despite anti-tumor necrosis factor α (TNF-α), were treated by intense immune suppression and autologous hematopoietic stem cell transplantation (HSCT). Stem cells were mobilized from the peripheral blood using cyclophosphamide (2.0 g/m2) and granulocyte colony-stimulating factor (G-CSF; 5 μg/kg/d), enriched ex vivo by CD34+ selection, and reinfused after immune conditioning with cyclophosphamide (200 mg/kg) and equine anti-thymocyte globulin (ATG; 90 mg/kg). Patients have remained in remission (CDAI < 100) for 1 year since HSCT. We conclude that further HSCT studies for severe Crohn disease appear warranted. © 2003 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Burt, R. K., Traynor, A., Oyama, Y., & Craig, R. (2003). High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood, 101(5), 2064–2066. https://doi.org/10.1182/blood-2002-07-2122

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free